Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab ...

Presentation will include an update on the development and launch preparations of Cylembio™ (imsapepimut and etimupepimut, adjuvanted)NEW YORK, ...

In the initial publication in 2021, the KETYNOTE-564 trial demonstrated that adjuvant pembrolizumab was associated with ...

Based on positive Phase 1/2 first line metastatic melanoma data, IO102-IO103, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), has been granted a Breakthrough Therapy ...

for untreated unresectable locally advanced non-small-cell lung cancer [ID6399] Technology appraisal guidance Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270 ...

2 The ongoing multicenter international randomized phase 2 study INTerpath-004 (NCT06307431) is comparing a PCV in combination with pembrolizumab (Keytruda) vs placebo plus pembrolizumab in the ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...